Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma

doi:10.4251/wjgo.v17.i4.101371

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (74)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

HTML

Figures (1-3)

Tables (1-4)

Sum=73

Apr 15, 2025 (publication date) through Mar 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 101371
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.101371

Open in New Tab Full Size Figure Download Figure

Figure 1 Research flowchart. HCC: Hepatocellular carcinoma; PCT: Postoperative combined therapy; PSM: Propensity score matching; IPTW: Inverse probability of treatment weighting; TACE: Transcatheter arterial chemoembolization; PD-1: Programmed death 1; PD-L1: Programmed death ligand 1; VEGFR: Vascular endothelial growth factor receptor.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier analysis of recurrence-free survival and overall survival before and after propensity score matching or inverse probability of treatment weighting. A: Recurrence-free survival (RFS) before propensity score matching and inverse probability of treatment weighting; B: RFS after propensity score matching; C: RFS after inverse probability of treatment weighting; D: Overall survival (OS) before propensity score matching and inverse probability of treatment weighting; E: OS after propensity score matching; F: OS after inverse probability of treatment weighting. PCT: Postoperative combined therapy; PSM: Propensity score matching; IPTW: Inverse probability of treatment weighting; RFS: Recurrence-free survival; OS: Overall survival; IQR: Interquartile range; FU: Follow up; HR: Hazard ratio; CI: Confidence interval; NA: Not available.

Open in New Tab Full Size Figure Download Figure

Figure 3 Line plots after generalized estimating equation for repeated measures of liver function. A: Generalized estimating equation modelling results for alanine aminotransferase; B: Generalized estimating equation modelling results for aspartate aminotransaminase; C: Generalized estimating equation modelling results for ln (gamma glutamyl transferase); D: Generalized estimating equation modelling results for alkaline phosphatase; E: Generalized estimating equation modelling results for albumin; F: Generalized estimating equation modelling results for total bilirubin; Vertical coordinates represent mean SEs. ^aP < 0.05. PCT: Postoperative combined therapy; ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransaminase; GGT: Gamma glutamyl transferase; TBIL: Total bilirubin.

Citation: Lu JL, Cheng Y, Xu ZL, Qian GX, Wei MT, Jia WD. Immune checkpoint inhibitors plus anti-angiogenesis in patients with resected high-risk hepatitis B virus-associated hepatocellular carcinoma. World J Gastrointest Oncol 2025; 17(4): 101371
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/101371.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.101371